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treatment before laparoscopic myomectomy: Efficacy and
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OBJECTIVE: Aims of our study were as follows: (1) to evaluate the therapeutic efficacy of the preoperative
administration of a gonadotropin-releasing hormone analog before laparoscopic myomectomy and (2) to as-
sess whether any ultrasonographic parameter of the fibroids (number, size, Doppler velocimetry, or
echogenicity) was of prognostic value.
STUDY DESIGN: A prospective randomized study was performed on 67 patients with symptomatic uterine fi-
broids that were mainly intramural; these patients were undergoing laparoscopic myomectomy. Patients were
randomized either to preoperative administration of two injections of a depot formulation of leuprolide acetate
28 days apart (group A, n = 35) or to direct surgery (group B, n = 32). In each group we studied the number,
volume, and echogenicity of the larger fibroids; the resistance index of uterine arteries and of fibroid vessels;
hematologic parameters; operative time; and blood loss.
RESULTS: The two groups did not differ significantly in basal ultrasonographic parameters and hematologic
data. Postoperatively, the red blood cell count and the serum hemoglobin and iron levels were significantly 
(p < 0.05) lower in group B. Both blood loss (p < 0.01) and operative time (p < 0.05) were significantly lower
in group A. However, the operative time was significantly longer when the main fibroid was markedly hypoe-
choic, probably because the increased softness of the tumor after leuprolide acetate pretreatment makes its
enucleation much more cumbersome.
CONCLUSION: Our data confirm the therapeutic efficacy of preoperative administration of a gonadotropin-
releasing hormone analog before laparoscopic myomectomy in reducing the blood loss and in decreasing
the operative time. This preoperative course of leuprolide acetate in hypoechoic fibroids, because of the fur-
ther reduction of the density of the myomas, causes a significant (p < 0.05) increase in operative time. (Am J
Obstet Gynecol 1998;178:108-12.) 
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Although still controversial,1-5 laparoscopic myomec-
tomy is becoming increasingly more common for the
treatment of symptomatic intramural fibroids, probably
because laparoscopic surgeons are becoming more profi-
cient in intracorporeal suturing.
A logical attempt to make this type of surgery easier
and faster is to reduce the myoma size and the blood flow
to the uterus6 by means of preoperative gonadotropin-re-
leasing hormone (GnRH) analog therapy. However, pre-
operative GnRH analog treatment has been reported to
cause an increased risk of recurrence,7 a possible delay in
the diagnosis of leiomyosarcoma,8 a risk of massive hem-
orrhage from degeneration,6 a greater difficulty in find-
ing the cleavage plane,9 and a greater extent of hyalin-
ization phenomena.10 Nevertheless, the reduction of
myoma volume and the decreased vascularity of the
uterus may represent important factors in facilitating la-
paroscopic myomectomy and improving results.11, 12
To assess the therapeutic efficacy of the preoperative
GnRH analog treatment in laparoscopic myomectomy,
we conducted this prospectively randomized study in 74
patients with symptoms who were scheduled for my-
omectomy. We compared the operative time, the blood
loss, and the hematologic parameters between the two
groups, and we correlated the results with the preopera-
tive ultrasonographic findings.
Material and methods
From September 1994 to July 1996, 74 women with
symptomatic uterine fibroids, who were referred to the
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and who were shown to fit the entry criteria, were in-
cluded in the randomized trial. The study was approved
by the Department Ethical Committee, and written in-
formed consent was obtained from each patient.
Inclusion criteria were (1) history of infertility lasting
>3 years or recurrent abortions; (2) symptoms of in-
creased vaginal bleeding, pelvic pain, or pelvic pressure;
(3) lack of pedunculation of the main myoma with an ul-
trasonographic size <500 cm3 but >4 cm3; (4) presence of
no more than four myomas per patient; (5) absence of
submucosal fibroids as screened by hysteroscopy; (6) ab-
sence of ultrasonographically documented calcification
in the main myoma; (7) absence of hyperplasia with cyto-
logic atypia in the endometrial biopsy performed be-
cause of menometrorrhagia; (8) absence of abnormal
Papanicolaou smear; and (9) negative urine pregnancy
test result.
The enrolled patients were allocated to one of the two
groups according to the same computer-generated ran-
dom assignment for both centers: Group A received the
GnRH analog pretreatment and group B underwent di-
rect surgery.
In group A two intramuscular injections of leuprolide
acetate 3.75 mg (Enantone, Takeda, Rome) were admin-
istered to each patient 4 weeks apart starting in the luteal
phase or within the first 2 days of menses, and the la-
paroscopic myomectomy was performed 2 to 5 weeks
after the second injection.
Ultrasonographic evaluations of uterine volume and
the number and volume of the myomas were performed
with an Aloka SSD 680 (Aloka Co., Tokyo) device with ei-
ther a 3.5 MHz transabdominal transducer or a 5 MHz
transvaginal probe by means of the ellipsoid formula D1
´ D2 ´ D3 ´ 0.5233 (D1, D2, and D3, respectively, were
the length and the transverse and anteroposterior diame-
ters).
A pulsed-wave duplex system with the same sector scan-
ner and a high-pass filter of 100 Hz was used to obtain the
blood flow velocity waveforms of uterine arteries and,
when possible, of the major vessels supplying identifiable
fibroids. The peak systole (A) and peak diastole (B) were
measured to calculate (A – B/A) the resistance index, with
the mean values of three consecutive measurements taken
into account and a coefficient of variation of 2% to 4%.
The echogenicity of the main fibroid was evaluated by
means of a relative score of 1 to 7, with 5 considered as
isoechogenic to the surrounding myometrium.
All of the above-cited ultrasonographic determinations
were performed on admission of the patient into the
study (T0) and in group A immediately before surgery
(T1). A complete blood cell count with differential count
and the serum hemoglobin and iron levels were obtained
at admission (T0), before surgery (T1), and 1 week after
surgery (Tf). 
Laparoscopic myomectomy was performed by use of a
10 mm scope (Karl Storz, Tuttlingen, Germany) with two
or three ancillary ports. The first step was always the infil-
tration of the fibroid base with up to 20 ml of octapressin
(Por-8, Sandoz, Basel, Switzerland) 5 IU in 1 ml diluted
1:30 followed by a longitudinal, possibly close to the mid-
line, unipolar or hook scissors incision. After the identifi-
cation of the cleavage plane, the fibroid was enucleated
by means of adequate traction with a myoma drill or a
strong grasper and counter traction maneuvers with
Manhes forceps, scissors, or hydrodissection instruments.
Coagulation of significant bleeders was obtained with
bipolar forceps, and the myometrial edges were reap-
proximated in one or two layers according to the depth
of the uterine wound, by means of Vicryl CT 2-0 (Ethicon
SpA, Pratica di Mare, Rome) polyglactin interrupted fig-
ure-of-eight sutures. The fibroids were removed in 41
cases with a 15 mm Semm (Wisap, Sauerlach, Germany)
morcellator13 and in the remaining 26 cases with a 12
mm Steiner (Karl Storz) automatic morcellator.14
At surgery (Ts) the entire operative time was noted.
The blood loss was evaluated as the balance between the
aspirated fluid and the irrigated liquid. In all cases opera-
tive samples were submitted for pathologic examination.
All randomized patients recruited for the study for
whom data were available were included in the efficacy
analysis. Statistical significance of between-group com-
parisons was assessed by c2 test for proportions, and the
Student t test for paired data has been used for compari-
son of data between T0 and T1. The Student t test for un-
paired data has been used for comparison between
groups A and B, when appropriate. Duration of opera-
tion and intraoperative blood loss were analyzed with the
Wilcoxon rank-sum test. Furthermore, for multiple com-
parison an analysis of variance with repeated measures
was used. The power analysis of the study is reported at
the beginning of the Comment section. In all analyses
statistical significance was assessed at the 5% level.
Results
At the time of laparoscopy 7 cases (2 in group A and 5
in group B) were excluded from the study either because
the main fibroid was pedunculated or <4 cm3 in volume
or because there was an association with severe adhesions
or endometriosis.
The 67 patients included in the study were aged 24 to
45 years (mean ± SD 37.2 ± 4.0), with a parity range of 0
to 3 (mean ± SD 1.4 ± 0.6) and a weight range of 55.4 to
79.6 kg (mean ± SD 63.6 ± 4.7).
At admission (T0) the two groups were not different in
age, parity, weight, and indications to surgery (Table I).
Uterine volume, number of fibroids, volume of main fi-
broid, echogenicity of main fibroid, resistance index of
uterine arteries, resistance index of main fibroid vessels,
red blood cell count, and serum hemoglobin and iron
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levels were not significantly different between groups at
admission (Table II).
In group A the two injections of GnRH analog signifi-
cantly reduced the uterine volume, the volume of the
main fibroid, and the echogenicity of the main leiomy-
oma. The number of fibroids found at the time of admis-
sion ultrasonography was always confirmed at the time of
laparoscopy. The uterine arteries and the resistance
index of the main fibroid vessels were significantly in-
creased preoperatively, proving that the flow was de-
creased after leuprolide treatment (Table II).
Postoperatively, the red blood cell count and the
serum hemoglobin and iron levels were lower in group
B. Both blood loss and operative time were significantly
lower in group A (p < 0.01 and p < 0.05, respectively)
(Table III).
The extraction time was significantly shorter in those
cases in which the Steiner morcellator was used in both
group A and group B (12.2 ± 8.1 vs 19.8 ± 12.3, p < 0.05),
but the cases in which the automatic morcellator was
used were equally distributed between the two groups
(13 cases in group A and 13 in group B).
Among the ultrasonographic parameters evaluated at
admission any significant difference in the operative pa-
rameters was shown to be related to the Doppler ve-
locimetry of uterine vessels and the major vessels of the
main fibroid.
Both more than two myomas and main fibroid volume
greater than 60 cm3 showed a significant improvement in
the operative time when pretreated by a 2-month course
of GnRH analog (Table IV). Particularly interesting are
the surgical correlations of the parameter echogenicity
of the main fibroid. The cases with a basal fibroid
echogenicity of <3 showed a significantly (p < 0.01)
longer surgery time after treatment with a GnRH analog
than was found for the rest of the pretreated fibroids or
the untreated patients (group B) with hypoechoic my-
omas (Table IV).
We had no significant complications and none of the
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procedures was converted to laparotomy. We had 4 pa-
tients with a transient postoperative fever (<39° C), 2 in
each group, and a pelvic mass (hematocele?) <5 cm in di-
ameter that developed in one patient resolved sponta-
neously within 3 weeks. Blood transfusion with 2 units of
packed red blood cells was required in one patient from
the subgroup of pretreated hypoechoic fibroids.
For all 67 patients we have a clinical follow-up of at
least 6 months. Abnormal uterine bleeding recurred in 4
out of 25 patients (16.0%). In patients with infertility or
abortion a pregnancy rate of 42.5% (17/40), with an
abortion rate of 23.5%, was obtained, Three patients
among the infertility group who did not became preg-
nant underwent a diagnostic microlaparoscopy after 6
months. In 2 of these 3 women filmy adhesions were de-
tected at the site of hysterotomy. Three of the 12 patients
(25.0%) referred with symptoms of pelvic pain com-
plained of pain of similar intensity at the 6-month follow-
up.
Comment
Uterine fibroids are the most common benign gyneco-
logic tumors but in patients with symptoms they should
be removed.15-18 Currently, laparoscopic myomectomy is
still controversial but is becoming more and more com-
mon.4, 19, 20 The use of preoperative GnRH analog has
been advocated in the hope that it may make surgery eas-
ier and faster by reducing the myoma size and blood loss.
Indeed, previous studies have suggested that the preop-
erative GnRH course (2 to 3 months) before myomec-
tomies performed by laparotomy has been effective in re-
ducing the blood loss,21 especially in patients with uteri
>600 cm3.22
The increased recurrence rate associated with GnRH
analog7 seems to be related more to the number of fi-
broids23 than to the preoperative medical treatment.
More important, the recurrence rate is not associated
with a greater reintervention rate, quoted as low as
10%.19 Currently, however, there is no report showing
the therapeutic efficacy of preoperative GnRH agonist
treatment before laparoscopic myomectomy.
In this prospectively randomized study we selected
only cases in which the main fibroids were intramural
and reconstruction of the uterine walls with sutures was
necessary. This selection was necessary to obtain a homo-
geneous series of cases with comparable surgical diffi-
culty.
The power analysis of this study for the outcome mea-
sure “operative time” showed a value of b = 0.898 with a
power of 0.102. Regarding blood loss, the other main
outcome parameter, b = 0.939 with a power of 0.061.
Therefore the sample size provided a power >90% to de-
tect such a difference in comparing the two groups at the
5% significance level.
Our results confirm the feasibility of laparoscopic my-
Table I. Patients’ characteristics
Group A Group B 
Characteristic (n = 35) (n = 32) Significance
Age (yr, mean ± SD) 36.8 ± 4.1 37.7 ± 3.9 NS
Weight (kg, mean 64.4 ± 4.6 62.8 ± 4.4 NS
± SD)
Parity (mean ± SD) 1.4 ± 0.7 1.5 ± 0.5 NS
Indication for 15 (42.8%) 10 (31.2%) NS
myomectomy (No.)
Abnormal uterine 8 (22.9%) 9 (28.1%) NS
bleeding
Infertility 7 (20.0%) 6 (18.8%) NS
Abortion 5 (14.3%) 7 (21.9%) NS
Pain
NS, Not significant.
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omectomy and subsequent uterine wall reconstruction.
The preoperative administration of GnRH analog re-
sulted in significantly lower blood loss at surgery,
lower operative time, and significantly higher red
blood cell count and hemoglobin and iron levels post-
operatively.
In regard to concerns related to the ultrasonographic
predictors, as expected, when the number of fibroids was
more than two and the volume of the main fibroid was
>60 cm3, we had a significant improvement in the opera-
tive time after the preoperative 2-month course of GnRH
analog. Doppler velocimetry of the uterine vessels and
the major vessels of the main fibroid24 did not show any
correlation with the efficacy of the GnRH analog preop-
erative treatment in reducing the operative time.
Inversely, when we consider those fibroids with an
echogenicity score <3, the pretreated group had a signifi-
cantly longer operative time (p < 0.05). Considering the
Table II. Ultrasonographic and hematochemical characteristics
Group A (n = 35) Group B (n = 32)
T0 T1 T0
Uterine volume (cm3) 473 ± 88† 396 ± 79 458 ± 92
No. of fibroids 2.1 ± 0.4 2.1 ± 0.4 1.9 ± 0.5
Main volume of fibroids (cm3) 62.8 ± 27.7† 41.5 ± 24.2 58.5 ± 31.0
Echogenicity of main fibroid 5.1 ± 1.3† 3.4 ± 0.9 4.8 ± 1.5
Resistance index
Uterine artery 0.66 ± 0.07† 0.79 ± 0.08 0.63 ± 0.08
Main fibroid 0.53 ± 0.08† 0.77 ± 0.06 0.55 ± 0.07
Values are presented as mean ± SD. There were no significant differences between groups at T0 for all parameters.
*T1, group A, versus T0, group B, p < 0.01.
†T0, group A, versus T1, p < 0.001.
Table III. Main outcome measures
Group A (n = 35) Group B (n = 32)
Global operative time (min, mean ± SD) 98.5 ± 26.1* 113.3 ± 35.1*
Blood loss (ml, mean ± SD) 171.8 ± 70.9† 232.1 ± 68.1†
Red blood cell count (´106/ml) 4.6 ± 0.3‡ 4.3 ± 0.5§ 4.4 ± 0.4‡ 3.9 ± 0.6§
Hemoglobin (gm/dl) 13.1 ± 0.8‡ 12.2 ± 1.1§ 12.7 ± 1.0‡ 11.4 ± 1.3§
Serum iron (mg/dl) 62.6 ± 14.2‡ 57.1 ± 12.8N§ 60.7 ± 13.9‡ 53.4 ± 12.3§
Change in T0 to Tf, group A versus group B, p < 0.05.
*Group A versus group B, p < 0.05.
†Group A versus group B, p < 0.01.
‡T0 versus Tf, p < 0.05.
§Tf, group A, versus Tf, group B, p < 0.05.
Table IV. Operative time as function of ultrasonographic predictors
Operative time (min)
Group A Group B
No. of fibroids
<3 91.4 ± 24.0 (n = 24) 99.9 ± 32.7 (n = 21)   
†
>3 114.1 ± 24.5 (n = 11) 139.0 ± 24.4 (n = 11)   
Volume of main fibroid
<60 ml 89.7 ± 22.3 (n = 20) 96.5 ± 29.6 (n = 20)   
‡
>60 ml 110.4 ± 26.8 (n = 15) 141.3 ± 24.6 (n = 12)   
Echogenicity of main fibroid
<3 128.3 ± 17.6 (n = 9) 114.9 ± 8.1(n = 10)       
>3 88.2 ± 20.0 (n = 26) 112.6 ± 42.4 (n = 22)   
Values in parentheses are numbers of patients. Operative time in minutes.
*p < 0.05.
†p < 0.01.
‡p < 0.001.
*
*
‡
*
†
*
*
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predominant relevance of the traction maneuvers in la-
paroscopic myomectomy, the difficulty in adequately
grasping the tumor is the key element in the longer op-
erative time. The softening of the fibroid tissue is proba-
bly related to degenerative changes induced by the
GnRH analog pretreatment,10 particularly in those fi-
broids without an adequate fibrous “skeleton” and thus
with the appearance as hypoechoic at the admission ul-
trasonography. From a pathologic point of view, these fi-
broids, when pretreated, showed a predominance of
areas of coagulative necrosis and mixoid degeneration.
Furthermore, the pretreated patients with hypoechoic
main fibroids had a longer surgery time than the rest of
the pretreated patients and the untreated patients with
hypoechoic myomas, showing unequivocally the negative
effect of preoperative GnRH analog treatment for these
kinds of uterine fibroids.
These data clearly show how the efficacy of a 2-month
course of GnRH analog in reducing blood loss before
laparoscopic myomectomy requiring wall reconstruc-
tion is well documented in our study. Furthermore, our
data show the effectiveness of pretreatment related to
the operative time in fibroids ³60 cm3, in multiple fi-
broids, and, comprehensively, in all cases except hypoe-
choic fibroids. In these fibroids preoperative GnRH
analog treatment further lowers the density of the
tumor, thereby causing the enucleation of the fibroid
from the uterine walls to be much more cumber-
some.22, 25
In conclusion, from our prospective randomized com-
parative study we can suggest the use of GnRH analog
pretreatment before laparoscopic myomectomy requir-
ing wall reconstruction in all cases except markedly hy-
poechoic fibroids.
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